Trial Profile
An Open-Label Tolerability and Exploratory Efficacy Study of Zonisamide for Dyskinesias in Parkinson's Disease
Status:
Suspended
Phase of Trial:
Phase IV
Latest Information Update: 24 Nov 2021
Price :
$35
*
At a glance
- Drugs Zonisamide (Primary)
- Indications Dyskinesias; Parkinson's disease
- Focus Therapeutic Use
- 15 Nov 2021 Planned End Date changed from 31 Dec 2018 to 31 Dec 2022.
- 15 Nov 2021 Planned primary completion date changed from 1 Apr 2018 to 1 Dec 2022.
- 15 Nov 2021 Status changed from recruiting to suspended (Site staffing).